This study was designed to determine the impact of maternal HIV-1 specific immunity on HIV-DNA immunization of 2 weeks old pups during the breast-feeding period.
Introduction
In early life, during and a few weeks after birth neonates are normally deficient in their ability to respond potently to invading pathogens. Newborn individuals thus rely heavily upon passively transferred antibodies from the mother. In mammalians, the transfer of antibodies may occur both during fetal life and through breast-feeding after birth. However, with the risk of early life exposure to certain microorganisms it would be highly desirable to induce adaptive immunity in neonates, immunity that can combat infectious agents when the passively transferred maternal immune protection recedes. Several infections, such as diarrhoeal infections or infections that can be transmitted from mother to child, such as Cytomegalovirus (CMV), Hepatitis B virus (HBV) or Human immunodeficiency virus (HIV-1) can be fatal in the neonatal period, particularly in developing countries. Hence, immunization during early life would be an attractive mean to provide solid and long-lasting immunity. As HIV-1 remains one of the major global killers it is of importance to develop vaccines that can be used early after birth and have the capacity to provide long-lasting both cell-mediated and humoral neutralizing immunity the virus.
It is important to understand the plasticity and functionality during development of the early fetal or neonatal immune system when aiming at inducing long-lasting immunity by early age vaccination. The classical view is that antigen presented during the fetal life may result in immunological tolerance against the antigen. However, exceptions to this dogma exist as shown by the importance of cell-mediated immunity against intracellular pathogens during early life. Immunized female mice will deliver a potent mucosal immunity in form of secretory IgA to the mucosal surface of their children during the breast-feeding. It is important to study how this transfer of antibodies will influence the immune responses in the pups after mucosal immunization and also to understand, which vaccine strategy that will provide potent immunity in the pups. 
Materials and Methods

Animals, vaccine candidates, adjuvants and immunization
The groups of females, immunization protocol and the grouping of the pups are summarized in Table 1 . Female C57Bl/6 mice of the H-2 b/d haplotype were immunized three times with 4 week intervals 10 μg plasmids encoding HIV-1subtype B gp160Env, p37Gag, Nef, Tat and Rev [8, 9] and subsequently boosted once with 10 ug recombinant gp160Env, p24Gag and Rev. The female mice were divided into four groups and were immunized either intranasally (group 1 and 2) or intradermally (group 3 and 4). Group 1 did not receive any adjuvant whereas group 2, received Parallell Solution, Cambridge, USA) in 50 μl PBS [10] . Group 3 was immunized intradermally without adjuvant wheras group 4 received recombinant murine GM-CSF (1 μg/mouse, ProSpecTany TechnoGene Ltd, Rehovot, Israel). All HIV-genes were carried by the plasmid pKCMV [8] .
One control -group of eight saline treated mice was included (Group 5) as well as one group of 6 mice given PCPP only (Group 6). One booster immunization with 1 μg of each recombinant HIV-1 antigens gp160Env, p24Gag, Nef, Rev and Tat antigen dissolved in PBS with or without PCPP adjuvant was given.
After the final booster immunization the female mice were selected for mating and the off-spring immunized within 15-18 days after birth, still during the breast feeding-period. All immunizations were performed under anesthesia with 4% isofluran (Abbott Scandinavia, Solna, Sweden). The pups (enumerated P1-P9) were at day 15-17 after birth given one single dose of 10
μg HIV-1 DNA, either intramuscularly or intranasally, with or without PCPP adjuvant. The pups received the DNA in a total volume of 20µl and the immunization was divided into two time points with 7 hours interval in order to reduce the risk that the immunogens would reach the lungs. Three weeks later (day 36 after birth) the pups immunized with 5 μg recombinant HIVproteins. Mice were sacrificed at three or six weeks after the final immunization.
Each group of HIV-1 immunized pups was divided into pups receiving the HIV-DNA intramuscularly into the hind right and left quadriceps muscle without adjuvant (Group P1 or P5)
or with PCPP as adjuvant (Group P3 or P7). Furthermore, HIV-1 immunized pups were divided into pups receiving the HIV-DNA intranasally without adjuvant (Group P2, P6) or with PCPP as adjuvant (Group P4 and P8). Finally, one group of pups born to non-vaccinated mothers and given only saline or PCPP intranasally was used as controls (Group P9).
Samples collection
Blood was obtained from each mouse by tail bleedings at two-week intervals after each immunization, and at the same time feces were collected. Serum was stored at -20 o C until used.
Mucosal samples were collected as previously described [11] [12] [13] [14] . Briefly, the fecal pellets were collected in PBS supplemented with protease inhibitors (Sigma-Aldrich, S:t Louis) and stored at -70 o C until used. HIV-1 antigen-specific serum IgG and IgA as well as fecal IgA reactivity was analyzed by ELISA and in HIV-1 neutralization assays. T-cell immunity was analyzed by T-cell proliferation and ELIspot IFN-γ and IL-2 cytokine release assays.
Enzyme-linked immunosorbent assay (ELISA) for detection of IgG and IgA antibodies
Ninety-six well plates (NUNC-Maxisorp, Odense, Denmark) were coated with recombinant HIV-1 proteins p24Gag (0.5 μg/ml), recombinant gp160Env (0,5 μg/ml, BioSciences Int, CT), Nef (0,5 μg/ml, kindly provided by Dr. V.Erfle, GSF, Munich, Germany) and Tat (1 μg/ml, kindly provided by C, Svanholm, KI, Stockholm). Sera were diluted in phosphate buffer saline (pH 7.4) with 0.5% bovine serum albumine (BSA, Boehring Mannheim, Mannheim, Germany) and 0.05% Tween 20 (Sigma, Aldrich, Sweden, AB) and 100μl of dilutions 1/50, 1/100, 1/1000, 1/10 000 and 1/100 000 were added to each well and incubated at +37 o C for 1,5 h. Mucosal samples were analyzed as previously described [13] [14] [15] and 200μl of the cell suspensions were added to each well and incubated at +37 o C for 72 hours.
At day 3, plates were washed three times with PBS containing 0.05% Tween 20 and tracing of bound murine IgG and IgA was performed as described above.
HIV-1 neutralization assay
Sera collected from immunized and control mice were tested for their HIV-1 neutralizing capacity in vitro as previously described [8, 16] . In brief, serially diluted heat-inactivated serum 
T-cell proliferation
The antigen-specific proliferation of lymphocytes was analyzed as described previously [11, 12] .
Antigens used were recombinant proteins gp160Env, p24Gag, Nef and Tat and synthetic 15-mer peptides representing HIV-1 gp120 V3.
Peptide synthesis
The peptides corresponding to the gp120 V3-loop region (aa 298-322/IHIGPGRAFV) and gp41 neutralizing epitope synthesized were: aa661-675/ELDKWAS (Hybaid T-peptides, Ulm, Germany). The p55Gag and gp160Env-peptide pools were obtained from the US National
Institutes of Health HIV-reagent repository (NIH, Washington, MA) and used in the ELISpot analyses [17] .
Statistical analyses
Statistical comparisons between the groups were performed using the nonparametric MannWhitney U test. A significant difference was considered when a p-value of <0.05 was obtained.
One-way ANOVA with Dunnetts post-test was performed using GraphPad Prism version 4.0a for MacIntosh, OS 9, Apple GraphicPad Software, San Diego, CA was used for comparisons of medians between groups at p<0.001 and p<0.05 levels.
Results
Humoral immune responses in adult mice
Humoral immune responses studied during 6 weeks after the protein booster immunization (for immunization protocol see Table 1 ), by testing the presence of HIV-1 specific p24Gag, gp160Env, Nef and Tat IgG and IgA in serum of adult mice. The HIV-1 specific serum antibody titers and the presence of HIV-1 neutralizing activity in the sera are shown in Table 2A and 2C, respectively. After protein boost, all HIV-immunized adult mice developed HIV-1 specific immunity against the four studied HIV-1 antigens, independently of route of immunization and use of adjuvant (Table 2B) . Serum antibody responses against HIV-1 antigens were induced to higher titers after intranasal immunization than after intradermal immunization, both with and Mab anti-p24 74,000 <100 <100 <100
Mab anti-gp120 <100 960,000 <100 <100
Mab anti-Nef <100 <100 5500 <100
Mab anti-Tat <100 <100 <100 1100
Abbreviations: I.m = Intramuscular, I.n.a = Intranasal, I.d = Intradermal. GM-CSF = Granulocyte-macrophage colony stimulating factor. Values within parenthesis represents the 25th and 75th quartiles (Tables 2A and B) . Differences in the frequency of serum IgG/IgA responders were seen mainly after the first and the second immunizations, where animals given DNA-plasmids together with PCPP responded earlier, more broadly and more strongly than animals immunized without adjuvant (Table 2B) antigens (p24Gag and Nef, Table 3 ). However, a significantly broader immune responses (i.e.
reactivity directed against more of the included HIV-proteins) was detected in mice born to HIVimmune mothers (Table 4 p<0.001, Figures 1 and 2 A-D).
To more sensitively investigate if the pups had developed systemic humoral immune responses, B cells were isolated from spleen 6 weeks after protein immunization and cultured for three days Positive controls
Mab anti-p24 68,000 <100 <100 <100
Mab anti-gp120 <100 880,000 <100 <100
Mab abti-Nef <100 <100 4600 <100
Mab anti-Tat <100 <100 <100 1200
Abbreviations: I.m = Intramuscular, I.n.a = Intranasal, I.d = Intradermal. GM-CSF = Granulocyte-macrophage colony stimulating factor.NA=Not applicable Figure 3A-B) . These data suggest that the reactivity observed in the mice was not only due to passively transferred antibodies from the HIV+ mothers. Nonimmunized pups, either born to HIV-immune or non-immune mothers, did not demonstrate any HIV-1 Env-, Nef-or Tatspecific antibodies 6 weeks after the separation from the mother (Table 3B) . No anti-gag antibodies were detected in the pups 8 weeks after separation from the mother (data not shown).
Presence of HIV-1 neutralizing antibodies
Serum antibodies capable of neutralizing HIV-1 in vitro were observed in the adult mice (Table   2C ). The immunogens used were based upon the two viral strains IIIB and SF2 and high HIV-1 neutralizing serum titers were obtained against these two tissue culture adapted HIV-1 isolates isolates are more difficult to obtain at high titer. There was a trend toward higher serum neutralizing titers in sera collected from group 1 (i.na. no adjuvant), 2 (i.na. plus PCPP) and 4 (i.d plus rGM-CSF) then in sera from group 3 (i.d., no adjuvant) against the TCLA HIV-1 strains, but not against the 6920 primary isolates. Since, the sera were pooled to allow repeated neutralization 
Figure 1. Median serum IgG titers in pups born to HIV-1 immunized (Groups P1 to P4) or HIV-1 naïve (Group P5-P8) four weeks after HIV-1 gp160Env, p37Gag, nef and tat DNA and one recombinant HIV-1 protein immunization. The box-plots show the median titers and the 25% and 75% quartiles for each study group of pups and in (A) against p24Gag, with indicated significant differences in the IgG titers between the study groups (B) against gp160Env, with significant differences in the IgG titers between indicated groups. Significant differences in serum IgG titers indicated in (C) against
to P4 represents spleen B-cells from HIV-immunized pups born from HIV+ mothers and groups P5-P8 represents spleen B-cells from HIV-immunized pups born from HIV-mothers and group P9 represents B cells from pups born to non-vaccinated mothers but given saline or PCPP only. The box-plots show the median OD values and the 25% and 75% quartiles for each study group of pups and in (A) against p24Gag where the OD values of B-cells are shown and significant differences indicated and (B)
against gp160Env where significant differences are indicated. * p < 0.05, ** p < 0.01, *** p < 0.001.
assays no reliable statistical analyses could be performed to compare the differences in titers between the groups. In the pooled serum collected from the pups at 6 weeks post-immunization no or only weak HIV-1 neutralizing activity was seen, suggesting that further booster immunizations would be needed in order to obtain higher HIV-1 neutralizing titers.
HIV-1 specific IgA in fecal washes after immunizations
A mucosal (intestinal, IgA) response was observed in addition to systemic immune response (Table 2A and 3A, Figure 2A-D) . In pups in groups P2, P4 and P8 significant HIV-1 specific fecal IgA antibody titers were observed contrasting the results observed in intramuscularly immunized pups or pups immunized without the addition of adjuvant. were detected in equal frequency in all HIV-1 immunized study groups, no significant differences in magnitude between the groups were detected. No significant differences in cell-mediated responses between the different groups of DNA immunized animals were seen (data not shown).
Discussion
The HIV-1 specific serum and fecal antibody titers of the mothers clearly did not negatively influence the responses in the pups. On the contrary, the data obtained in this study suggest that broader HIV-1 specific humoral immunity was obtained when breast-feeding pups were
immunized with HIV-1 DNA prime and protein boost. Pups born of HIV-1 sero-negative mothers showed significantly lower as well as less broad immune responses. There are several possible explanations for the observed differences.
Firstly, the immunogens used, which includes DNA-plasmids. Plasmids are considered to be clean antigen-expressing agents and plasmids are not hampered by pre-existing immunity to the vector, as is the case for viral or bacterial vaccine vectors. Secondly, in the intranasal tissue, the concentrations of potentially blocking or inhibiting antibodies are lower then in, for instance serum. Thus allowing for more efficient antigen uptake and presentation by antigen-presenting cells. Thirdly, when it comes to the DNA prime and recombinant antigen boost, the maternal antibodies may bind to the antigen and form immune complexes that more efficiently are taken up by dendritic cells or B cells via FcR-mediated uptake mechanisms [18] . Lastly, since the pups had been fed with mother's milk containing HIV-specific immunoglobulins perhaps they have induced anti-idiotypic antibodies (complementary determining regions) which may have triggered and enhanced the B-cell immune responses in the pups [19] . The remarkable result was that the pups of the HIV+ mothers developed serum and fecal IgA antibodies against all four studied HIV-antigens. While the truly HIV-1 naïve pups responded immunologically very similar to untreated adult mice, the HIV-1 DNA-primed once and boosted with a low dose recombinant antigens once, resulting in humoral antibodies against one or two antigens. One possible explanation is that some of the immune reactivities can be due to remaining HIV-1 specific antibodies that are passively transferred from the mother to the offspring, even though we were able to detect them in the 20 control mice that we studied without immunization (Table 3) .
Furthermore, perhaps soluble factors in the mothers milk such as cytokines or chemokines, may influence the immune responsiveness of the breast-fed pup. This in combination with the nutrient-rich mothers milk may create a favorable immunological milieu in the pup making it more capable of responding to vaccination.
However, even though (at the time of immunization) the maternal antibody titers were relatively high (Table 1 ) and clearly detectable in pups at 4 weeks after terminated breast-feeding, the titers were not dramatically high. The neutralizing antibody titers were low which may at, to some degree, explain why the maternal antibodies did not have negative influence. In previous studies, using live vectors showed that when maternal antibody titers reach above a certain level, they were able to suppress vaccine-specific immune responses [20, 21] , probably by binding to and facilitating the clearance of vaccine antigen in the pups. Previous studies have been performed on much younger mice (1-7 days post-partum, or even in utero [1-3,22-24]) than the pups used in our study, in which the pups had reached their final days of breast-feeding (day 15-17) where after they were separated from the mother two to three days later.
It may also be of interest to discuss the immunity to HIV evoked in the adult female mothers. In, these studies we evaluated the primary immune responses against four HIV-antigens in both adults and pups that both were immunized with a heterologous DNA-prime and later with a recombinant protein boost. In, both populations the administrations were performed intranasally or parentally where the parental dose in the mothers was given intradermally and in the pups intramuscularly. Finally, the numbers of immunizations differed; the adult females were given three DNA-immunizations before they were finally boosted with protein while the pups were DNA-primed and protein-boosted once. The reasons for these differences were the following, it was important to obtain a full and clearly detectable humoral immunity in the mothers to be able to study if this complete HIV-1 antigen-specific repertoire could have effect when transferred to the pups. In the pups it was instead more important to investigate how broad and fast a HIV-1 specific humoral immunity could be obtained with as few immunizations as possible. The idea behind this decision was that in certain high risk HIV-1 exposure situations i.e HIV-infected mothers providing breast-milk to their children it may be critical to obtain the HIV-1 immunity rapidly and early in life to prevent infection and disease, as with many gastrointestinal or diarrheal orally transmitted diseases [23] . We did not immunize mothers intramuscularly since this route seldom gives efficient mucosal secretory IgA immunity. The aim was to investigate the impact of maternal antibodies transferred both via placenta (IgG) and via breast milk, both IgA and IgG.
Regarding the role of adjuvants in these experiments; in the mothers we tested two types of adjuvants, in the intranasally immunized mothers we delivered DNA and proteins with the PCPP, an adjuvant described as a antigen-deposit induced delivery. Thus, the DNA or the protein may This route would probably better reflect the natural situation as most pathogens enter across mucosal surfaces and that mothers thus often are both mucosally and systemically immune when delivering their offspring.
It is possible that with this immunization strategy for the adult mice was capable of providing immune-enhancing effects in the pups; this has been reported with other protein-based vaccines [25] . In other studies, with other vaccine candidates, problems with vaccine-take in the offspring after DNA immunization have been described if a very strong maternal humoral immunity is present. In these reports it seems as if the maternal antibody levels may have masked the vaccine antigen, even when they were given parentally as killed vaccines [1, 2, 22] . In this study, these difficulties were not seen, likely because the maternal antibody-titers against HIV antigens were not high enough to interfere with immunization. Furthermore, especially in mucosally immunized pups the presence of neutralizing antibodies may not have reach sufficient levels to interfere with vaccine administration and uptake. It seems clear from several previous reports that DNAimmunization of neonates, newborns or even in utero can induce vaccine-specific cellular immunity, as shown for Influenza virus, respiratory syncytial virus and Herpes virus [3, [26] [27] [28] [29] [30] [31] [32] .
Occasionally also antibody responses have been reported after DNA-prime and MVA-boost immunization against malaria, in this case antibodies were mainly found in neonates born of sero-negative mothers [33] . It is today clear that most HIV-1 transmissions occur via mucosal transmission, (reviewed in [34] ) and an immune response elicited by vaccination should act at mucosal surfaces to be efficient. To achieve this, a vaccine would probably be most efficacious if delivered via the mucosa, preferably intranasal or orally using needle-free devices. In addition, the systemic humoral and cellular responses are also believed to be important [35, 36] . It may thus be a good idea to search for immunization strategies that provide both strong systemic and mucosal CTL and neutralizing antibody responses against HIV-1.
In this study, we show that with the use of HIV-1 DNA and PCPP adjuvants it was possible to induce systemic and mucosal HIV-1 specific immunity, both cell-mediated and humoral.
Moreover, the responses were significantly broader in immunized pups born to mothers displaying HIV-1 specific immune responses. Although the duration of the immune responses in the pups is currently unknown, our data indicates a place for immune intervention in early life.
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